De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TiumBio Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Huntaek Kim

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	31.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Geen updates

Recent updates

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Jun 20

CEO

Huntaek Kim (58 yo)

no data

Tenure

Mr. Hun-Taek Kim serves as Chief Executive Officer of TiumBio Co. Ltd. He received his Bachelor's degree from College of Veterinary Medicine, Seoul National University, Master's degree from College of Vete...

TiumBio Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Recent updates

TiumBio Co., Ltd. Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting

TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer

New minor risk - Revenue size

New minor risk - Shareholder dilution

TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding

TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding

New 90-day low: ₩16,000

New 90-day high: ₩18,000

New 90-day high: ₩18,900

New 90-day high - ₩17,950

CEO

Tenure